Current solutions for accessing and analyzing pharmacodynamics information and profiles include consulting companies, companies that create and share profiles based on volunteer participants, and databases of literature. These solutions are outdated, hard to use, and oftentimes expensive, leaving scientists without the tools they need to succeed into preclinical research and Phase I trials.
The first solution to helping researchers utilize pharmacodynamic profiles is companies that provide consulting services to guide researchers through the process of identifying and creating a profile for the drug they are researching. One of the biggest companies serving this space is Nuventra, a pharma services company. Nuventra and other consulting companies will provide risk analysis, dosage simulations, drug-to-drug interaction studies, multiple ascending dose studies, and more to researchers. The downside to this solution is that each study costs $75K-200K, which can quickly add up.
Another solution is using studies done on healthy volunteers to understand the disease and other demographic models. One of the biggest companies in this space is Icon, which offers pharmacodynamic support through data they have collected based on studies done with healthy volunteers. The problem with this solution is that there are only studies available for the most common demographics and only offer broad insights into these groups. Another potential problem is the high cost associated with the data to cover the cost of the study.
One of the other solutions is to use databases that have compiled information from various pieces of literature. Some of the bigger databases in the space include JavaPK and PKDB. The issue with this solution is that oftentimes these databases are outdated as they are run by volunteers and do not include the most updated information on a disease or drug. The other issue is that they are hard to use, with multiple tabs to click through and a disorganized presentation of information.